Weill Cornell Medicine
1300 York Ave
New York
NY
10022
15 articles about Weill Cornell Medicine
-
Dr. Robert Harrington named dean of Weill Cornell Medicine
6/1/2023
Dr. Robert A. Harrington, a cardiologist and the Arthur L. Bloomfield Professor of Medicine and chair of the Department of Medicine at Stanford University, has been named the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University.
-
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
-
COVID-19 causes certain conditions or is being implicated in their earlier onset. Type 1 diabetes and Parkinson’s disease are prime examples. According to researchers, it also may cause fetal inflammation.
-
Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer
9/14/2021
Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa
-
A New Approach to Curing HIV
8/17/2021
Over the last 40 years, HIV has shifted from a deadly and mysterious virus to one that can be controlled with daily drugs. But attempts to completely eliminate the virus from the bodies of people living with HIV, curing them for good, have failed.
-
The Leukemia & Lymphoma Society Launches IMPACT Research Grants to Help Underserved Patients Access Clinical Trials
5/6/2021
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
-
Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of COVID-19 patients.
-
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
11/16/2020
Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque psoriasis
-
CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMapUroMap Gene Expression Test Will Add to CareDx’s Best In Class Transplant Surveillance Comprehensive Solutions
5/5/2020
CareDx, Inc. announced a strategic alliance with Weill Cornell Medicine that makes CareDx the exclusive development and commercialization partner of UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
-
Study Identifies the Molecular Mechanisms by which Noonan Syndrome RAF1 mutations cause Cardiac Hypertrophy
6/8/2019
Investigators from the Masonic Medical Research Institute, Weill Cornell Medicine and Beth Israel Deaconess Medical Center have identified the molecular mechanisms by which RAF1 mutations in patients with Noonan Syndrome cause hypertrophic cardiomyopathy, a dangerous thickening of the heart muscle that can lead to heart failure and death.
-
High-Fructose Corn Syrup Promotes Colon Tumor Growth in Mice
3/21/2019
Consuming the equivalent of one can of soda per day caused mice predisposed to colon cancer to develop larger tumors, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
-
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
-
July 13 Research Roundup: Gene Therapy for Cholesterol, Beta-Thalassemia, and Kidney Disease, and...
7/13/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them from gene therapy for cholesterol to kidney disease and more. -
Weill Cornell Medicine Joins TriNetX Health Research Network to Expand Breadth of Clinical Research
1/30/2018
TriNetX is a network comprised of healthcare organizations representing nearly 100 million patients globally, biopharmaceutical companies, and CROs.